Eintrag weiter verarbeiten
Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells: Whe...
Gespeichert in:
| Zeitschriftentitel: | Genetic Engineering & Biotechnology News |
|---|---|
| Personen und Körperschaften: | |
| In: | Genetic Engineering & Biotechnology News, 39, 2019, S1, S. S4-S5, S26 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Mary Ann Liebert Inc
|
| Schlagwörter: |
| author_facet |
Eisenstein, Michael Eisenstein, Michael |
|---|---|
| author |
Eisenstein, Michael |
| spellingShingle |
Eisenstein, Michael Genetic Engineering & Biotechnology News Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells Management of Technology and Innovation Biomedical Engineering Bioengineering Biotechnology |
| author_sort |
eisenstein, michael |
| spelling |
Eisenstein, Michael 1935-472X 1937-8661 Mary Ann Liebert Inc Management of Technology and Innovation Biomedical Engineering Bioengineering Biotechnology http://dx.doi.org/10.1089/gen.39.s1.02 Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells Genetic Engineering & Biotechnology News |
| doi_str_mv |
10.1089/gen.39.s1.02 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie Medizin Technik Chemie und Pharmazie Wirtschaftswissenschaften |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA4OS9nZW4uMzkuczEuMDI |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA4OS9nZW4uMzkuczEuMDI |
| institution |
DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 |
| imprint |
Mary Ann Liebert Inc, 2019 |
| imprint_str_mv |
Mary Ann Liebert Inc, 2019 |
| issn |
1935-472X 1937-8661 |
| issn_str_mv |
1935-472X 1937-8661 |
| language |
English |
| mega_collection |
Mary Ann Liebert Inc (CrossRef) |
| match_str |
eisenstein2019takinganewshotattumorvaccineswhethertheyfollowpersonalizedorofftheshelfstrategiesdevelopersareoptimisticabouttargetingantigensuniquetoaberrantcellswhethertheyfollowpersonalizedorofftheshelfstrategiesdevelopersareoptimisticabouttargetingantigensuniquetoaberrantcells |
| publishDateSort |
2019 |
| publisher |
Mary Ann Liebert Inc |
| recordtype |
ai |
| record_format |
ai |
| series |
Genetic Engineering & Biotechnology News |
| source_id |
49 |
| title_sub |
Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title |
Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_unstemmed |
Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_full |
Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_fullStr |
Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_full_unstemmed |
Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_short |
Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_sort |
taking a new shot at tumor vaccines : whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| topic |
Management of Technology and Innovation Biomedical Engineering Bioengineering Biotechnology |
| url |
http://dx.doi.org/10.1089/gen.39.s1.02 |
| publishDate |
2019 |
| physical |
S4-S5, S26 |
| description |
|
| container_issue |
S1 |
| container_start_page |
0 |
| container_title |
Genetic Engineering & Biotechnology News |
| container_volume |
39 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792326420932853770 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T12:21:14.192Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Taking+a+New+Shot+at+Tumor+Vaccines+%3A+Whether+they+follow+personalized+or+off-the-shelf+strategies%2C+developers+are+optimistic+about+targeting+antigens+unique+to+aberrant+cells&rft.date=2019-03-01&genre=article&issn=1937-8661&volume=39&issue=S1&pages=S4-S5%2C+S26&jtitle=Genetic+Engineering+%26+Biotechnology+News&atitle=Taking+a+New+Shot+at+Tumor+Vaccines+%3A+Whether+they+follow+personalized+or+off-the-shelf+strategies%2C+developers+are+optimistic+about+targeting+antigens+unique+to+aberrant+cells&aulast=Eisenstein&aufirst=Michael&rft_id=info%3Adoi%2F10.1089%2Fgen.39.s1.02&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792326420932853770 |
| author | Eisenstein, Michael |
| author_facet | Eisenstein, Michael, Eisenstein, Michael |
| author_sort | eisenstein, michael |
| container_issue | S1 |
| container_start_page | 0 |
| container_title | Genetic Engineering & Biotechnology News |
| container_volume | 39 |
| description | |
| doi_str_mv | 10.1089/gen.39.s1.02 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie, Medizin, Technik, Chemie und Pharmazie, Wirtschaftswissenschaften |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA4OS9nZW4uMzkuczEuMDI |
| imprint | Mary Ann Liebert Inc, 2019 |
| imprint_str_mv | Mary Ann Liebert Inc, 2019 |
| institution | DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1 |
| issn | 1935-472X, 1937-8661 |
| issn_str_mv | 1935-472X, 1937-8661 |
| language | English |
| last_indexed | 2024-03-01T12:21:14.192Z |
| match_str | eisenstein2019takinganewshotattumorvaccineswhethertheyfollowpersonalizedorofftheshelfstrategiesdevelopersareoptimisticabouttargetingantigensuniquetoaberrantcellswhethertheyfollowpersonalizedorofftheshelfstrategiesdevelopersareoptimisticabouttargetingantigensuniquetoaberrantcells |
| mega_collection | Mary Ann Liebert Inc (CrossRef) |
| physical | S4-S5, S26 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Mary Ann Liebert Inc |
| record_format | ai |
| recordtype | ai |
| series | Genetic Engineering & Biotechnology News |
| source_id | 49 |
| spelling | Eisenstein, Michael 1935-472X 1937-8661 Mary Ann Liebert Inc Management of Technology and Innovation Biomedical Engineering Bioengineering Biotechnology http://dx.doi.org/10.1089/gen.39.s1.02 Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells Genetic Engineering & Biotechnology News |
| spellingShingle | Eisenstein, Michael, Genetic Engineering & Biotechnology News, Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells, Management of Technology and Innovation, Biomedical Engineering, Bioengineering, Biotechnology |
| title | Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_full | Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_fullStr | Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_full_unstemmed | Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_short | Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_sort | taking a new shot at tumor vaccines : whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_sub | Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| title_unstemmed | Taking a New Shot at Tumor Vaccines : Whether they follow personalized or off-the-shelf strategies, developers are optimistic about targeting antigens unique to aberrant cells |
| topic | Management of Technology and Innovation, Biomedical Engineering, Bioengineering, Biotechnology |
| url | http://dx.doi.org/10.1089/gen.39.s1.02 |